News

Isotechnika, a Canada-based biopharmaceutical company, has reported positive 12-month follow-up data from the Phase IIb Promise trial evaluating its lead drug, voclosporin, a next generation calcineurin inhibitor, in

Pharmos Corporation, which discovers and develops therapeutics to treat diseases of the nervous system and autoimmune disorders, has issued 18 million shares of common stock and warrants exercisable

The proprietary, patented, and biocompatible polyvinyl alcohol polymer (PVA) membrane may reduce the risk of associated injury following anterior vertebral surgeries by providing a vessel cover, the company

According to Takeda, TAK-379 is an anti-diabetic agent categorized as an insulin sensitizer and was in the Phase II stage of development in the US and Europe, and

Alkermes has completed patient enrollment for the registration study of Vivitrol for the treatment of opioid dependence, a chronic brain disease. The Phase III randomized, multi-center study is

Under the terms of the agreement, Breg will continue to supply Novation with its comprehensive lines of functional, osteoarthritis, patellofemoral and postoperative knee braces. Additionally, under this new

Genentech has reported that a Phase III study of Avastin plus chemotherapy following surgery in patients with early-stage colon cancer did not meet its primary endpoint of reducing

Transave has completed patient enrollment in a Phase II study evaluating the safety and efficacy of Arikace in non-cystic fibrosis bronchiectasis patients. The double-blind, placebo-controlled study is designed

In this role, Mr Nicklas will oversee sales, marketing and managed care efforts for BTA’s products. Prior to joining Biovail, Mr Nicklas was senior director of epilepsy marketing